CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy
This study assesses computed tomography (CT) perfusion imaging in predicting treatment response in patients with non-small cell lung cancer or tumors that have spread from the primary site (place where it started) to the lungs (metastases) treated with stereotactic ablative radiation therapy. CT perfusion imaging is a special type of CT that uses an injected dye in order to see how blood flow through tissues, including lung tissue. CT perfusion imaging of the lungs may help doctors learn whether perfusion characteristics of lung tumors may be predictive of response to treatment and whether lung perfusion characteristics can be used to follow response to treatment.
Checked against the public recordLast updated Nov 22, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Stanford University
- Interventions being studied
- Device: CAPP-Seq; Drug: Isovue-200; Radiation: Computed Tomography Perfusion Imaging
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patients undergoing SABR for the treatment of a lung tumor, inclusive of non-small cell lung cancer or lung metastases Exclusion Criteria: * Patients who are pregnant or are trying to become pregnant are excluded from this study * Patients with renal failure, defined as glomerular filtration rate (GFR) \< 60 at the time of the radiation treatment-planning (RTP) scan, will be excluded
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Stanford University, School of MedicinePalo Alto, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 22, 2023. Always confirm current availability with the study team.